GRI Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GRI research report →
Price Chart
About the company
GRI Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
- CEO
- W. Marc Hertz
- IPO
- 2021
- Employees
- 4
- HQ
- La Jolla, CA, US
Get TickerSpark's AI analysis on GRI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.15M
- P/E
- -0.04
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.33
- EV/EBITDA
- 0.70
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -134.03%
- ROIC
- -93.76%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-11,977,000
- Net Income
- $-11,956,000-45.7%
- EPS
- $-121.80-37009.1%
- OCF Growth
- -18.3%
- FCF Growth
- -18.3%
- 52W High
- $64.12
- 52W Low
- $1.36
- 50D MA
- $1.84
- 200D MA
- $2.87
- Beta
- -0.61
- RSI (14)
- 48
- Avg Volume
- 328.73K
No earnings-call transcripts are available for GRI yet.
- Free Float
- 100.0%
- Shares Outstanding
- 2.19M
- Float Shares
- 2.19M
of shares held by institutions
6 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Hrt Financial LP | 28.78K | ▲ 28.78K |
| Vanguard Capital Management LLC | 21.37K | ▲ 21.37K |
| Geode Capital Management, LLC | 13.87K | ▼ 4.57K |
| Citadel Advisors LLC | 13.38K | ▲ 13.38K |
| Morgan Stanley | 8.74K | ▲ 8.74K |
| Ubs Group AG | 4.92K | ▼ 3.80K |
| Tower Research Capital LLC (Trc) | 2.43K | ▲ 1.37K |
| Barclays PLC | 83 | ▲ 83 |
| Blackrock, Inc. | 7 | 0 |
| Caitong International Asset Management Co., Ltd | 2 | ▲ 2 |
| Danske Bank A/S | 2 | 0 |
Held by 13 ETFs
Biggest fund positions in GRI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 18, 25 | Kelly Leanne | other | 43,222 |
| Sep 18, 25 | Szekeres David Leslie | other | 39,897 |
| Sep 18, 25 | Baker David Charles | other | 23,605 |
| Sep 18, 25 | SIMPSON CAMILLA V | other | 23,605 |
| Sep 18, 25 | Chaturvedi Vipin | other | 43,222 |
| Sep 18, 25 | Rongen Roelof | other | 23,605 |
| Sep 18, 25 | Hertz Walter Marc | other | 103,067 |
| Aug 26, 25 | Hertz Walter Marc | other | 26,688 |
| Aug 26, 25 | Szekeres David Leslie | other | 10,276 |
| Aug 26, 25 | Baker David Charles | other | 5,994 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GRI coverage
Recent articles, reports, and earnings notes.
No research on GRI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GRI report →GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
globenewswire.com · Sep 28
GRI Bio, Inc. (GRI) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com · Sep 14
UPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To Buy
benzinga.com · Sep 14
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars
globenewswire.com · Sep 8
GRI Bio Featured in "Why Now" On-Demand Video Webcast
globenewswire.com · Aug 27
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
globenewswire.com · Aug 24
Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks
nypost.com · Aug 20
Ingevity Releases 2025 Sustainability Report, Highlights Performance and Impact
gurufocus.com · Aug 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.